{
  "event_id": "96e3eea1fb27",
  "ticker": "GSK",
  "company_name": "GlaxoSmithKline",
  "drug_name": "TIVICAY PD",
  "pdufa_date": "20210323",
  "approval_type": {
    "status": "found",
    "value": "nda",
    "source": "websearch:P1093/ODYSSEY Phase 1/2 (2020)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T20:53:01.018913",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "Pediatric HIV (4+ weeks, 3+ kg)",
    "source": "websearch:P1093/ODYSSEY Phase 1/2 (2020)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T20:53:01.018915",
    "error": null
  },
  "generic_name": {
    "status": "found",
    "value": "dolutegravir",
    "source": "websearch_fda",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T07:18:32.440880",
    "error": null
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Infectious Disease",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:58.776613",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "websearch_clinical",
    "confidence": 0.85,
    "tier": 2,
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T07:18:32.440880",
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:P1093/ODYSSEY Phase 1/2 (2020)",
    "confidence": 0.9,
    "evidence": [
      "P1093/ODYSSEY Phase 1/2 (2020)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T20:53:01.018895",
    "error": null
  },
  "p_value": {
    "status": "not_applicable",
    "value": null,
    "source": "websearch:P1093/ODYSSEY Phase 1/2 (2020)",
    "confidence": 0.9,
    "evidence": [
      "Single-arm or accelerated approval - no comparator p-value"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T20:53:01.018905",
    "error": null
  },
  "p_value_numeric": null,
  "effect_size": {
    "status": "found",
    "value": "62% undetectable VL at 24 wks; 69% at 48 wks",
    "source": "websearch:P1093/ODYSSEY Phase 1/2 (2020)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T20:53:01.018908",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Na√Øve, Antiretroviral-Experienced Adults"
  ],
  "nct_ids": [
    "NCT01231516"
  ],
  "enrollment": {
    "value": 724,
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2
  },
  "has_prior_crl": {
    "status": "found",
    "value": true,
    "source": "derived_from_resubmission",
    "confidence": 0.85,
    "tier": 2
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": true,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.075,
  "collected_at": "2026-01-09T00:36:02.622217",
  "enriched_at": "2026-01-11T18:55:50.559946",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "24ebf209f8b2",
  "fda_designations": {
    "breakthrough_therapy": false,
    "fast_track": false,
    "priority_review": true,
    "orphan_drug": false,
    "accelerated_approval": false
  },
  "mechanism_of_action": "Integrase inhibitor",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -1754,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:39.771716",
  "is_single_arm": {
    "value": false,
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "interventionModel=PARALLEL",
      "allocation=RANDOMIZED"
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-11T08:31:15.267875",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "trial_region": {
    "value": "global",
    "status": "found",
    "source": "clinicaltrials.gov",
    "confidence": 0.95,
    "tier": 2,
    "evidence": [
      "countries=['HUNGARY', 'GREECE', 'RUSSIA', 'ROMANIA', 'FRANCE']..."
    ],
    "searched_sources": [
      "clinicaltrials.gov"
    ],
    "last_searched": "2026-01-11T08:31:15.267941",
    "error": null,
    "note": null,
    "has_value": true,
    "needs_retry": false,
    "is_complete": true
  },
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:38:45.240653"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:38:45.240661"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T18:55:32.856467",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T18:55:39.031714",
    "search_status": "CONFIRMED_NONE"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "ViiV Healthcare announces US FDA approval of the first-ever ... FDA approves Tivicay and Tivicay PD "
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T18:55:40.177061",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T18:55:46.147992",
    "search_status": "CONFIRMED_NONE"
  },
  "accelerated_approval": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "ViiV Healthcare announces US FDA approval of the first-ever ... PDS Biotechnology Amends Phase 3 Tri"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T18:55:50.559934",
    "search_status": "FOUND"
  }
}